311 filings
Page 7 of 16
8-K
mwtaelrj0kq qgxsu29
23 Sep 19
Oragenics, Inc. to Present Interim Data on AG013 at the European Society of
9:02am
8-K
v70ioybx52sgmgsq
6 Sep 19
Regulation FD Disclosure
5:20pm
8-K
vkonp
21 Jun 19
Submission of Matters to a Vote of Security Holders
4:48pm
8-K
2bgn90ydhldk
25 Mar 19
Oragenics Announces Closing of $12.5 Million Underwritten Public Offering
4:32pm
8-K
tglepjeefmqjk
21 Mar 19
Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering
9:26am
8-K
ybfqlytri3cs1v
20 Mar 19
Organics Announces Proposed Underwritten Public Offering
5:28pm
8-K
bao2m5lrtjwzzhx
15 Mar 19
Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
4:40pm
8-K
9kqwml9ek80zr
22 Feb 19
Departure of Directors or Certain Officers
5:01pm
8-K
hymlg5vt3102 b5k
21 Dec 18
Departure of Directors or Certain Officers
4:27pm
8-K
g6r7pvbhwfv14i
3 Dec 18
Regulation FD Disclosure
5:27pm
8-K
l92o5xxgzatxfglx4fbp
17 Oct 18
Oragenics, Inc. Receives Clearance to Enroll Patients In Belgium into Its
9:02am
8-K
z1gj2f3 yex5twpw0
5 Oct 18
Other Events
5:10pm
8-K
u1of0 q9w3ir
1 Oct 18
Departure of Directors or Certain Officers
4:02pm
8-K
bhdd ml4y666ohdf
25 Sep 18
Other Events
5:02pm
8-K
g3lh7ea3c
15 Aug 18
Regulation FD Disclosure
9:07am
8-K
ktdz1qugl
17 Jul 18
Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering
4:31pm
8-K
cx2ib2 i0hl7eaqo6zjt
13 Jul 18
Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering
8:35am
8-K
cubm26
26 Jun 18
Departure of Directors or Certain Officers
4:33pm
8-K
whtzqc bdv
11 Jun 18
Entry into a Material Definitive Agreement
5:00pm
8-K
56qshehwmq3 wj
30 May 18
Oragenics Reports Positive Interim Safety Analysis Results From Its Phase 2 Clinical Trial of AG013 for Oral Mucositis
9:17am